

Published in final edited form as:

*Nat Med.* 2010 December ; 16(12): . doi:10.1038/nm.2251.

## Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway

Zainab Jagani<sup>1</sup>, E Lorena Mora-Blanco<sup>2</sup>, Courtney G Sansam<sup>2</sup>, Elizabeth S McKenna<sup>2</sup>, Boris Wilson<sup>2</sup>, Dongshu Chen<sup>1</sup>, Justin Klekota<sup>1</sup>, Pablo Tamayo<sup>3</sup>, Phuong T L Nguyen<sup>2</sup>, Michael Tolstorukov<sup>4</sup>, Peter J Park<sup>4</sup>, Yoon-Jae Cho<sup>3,5</sup>, Kathy Hsiao<sup>1</sup>, Silvia Buonamici<sup>1</sup>, Scott L Pomeroy<sup>5</sup>, Jill P Mesirov<sup>3</sup>, Heinz Ruffner<sup>6</sup>, Tewis Bouwmeester<sup>6</sup>, Sarah J Luchansky<sup>1</sup>, Joshua Murtie<sup>1</sup>, Joseph F Kelleher<sup>1</sup>, Markus Warmuth<sup>1</sup>, William R Sellers<sup>1</sup>, Charles W M Roberts<sup>2,8</sup>, and Marion Dorsch<sup>1,7,8</sup>

<sup>1</sup>Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA <sup>2</sup>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Children's Hospital Boston, Boston, Massachusetts, USA <sup>3</sup>Broad Institute of Harvard and M.I.T, Cambridge, Massachusetts, USA <sup>4</sup>Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA <sup>5</sup>Department of Neurology, Children's Hospital Boston, Boston, Massachusetts, USA <sup>6</sup>Novartis Institutes for BioMedical Research, Basel, Switzerland

### Abstract

Aberrant activation of the Hedgehog (Hh) pathway can drive tumorigenesis<sup>1</sup>. To investigate the mechanism by which glioma-associated oncogene family zinc finger-1 (GLI1), a crucial effector of Hh signaling<sup>2</sup>, regulates Hh pathway activation, we searched for GLI1-interacting proteins. We report that the chromatin remodeling protein SNF5 (encoded by *SMARCB1*, hereafter called *SNF5*), which is inactivated in human malignant rhabdoid tumors (MRTs), interacts with GLI1. We show that Snf5 localizes to Gli1-regulated promoters and that loss of Snf5 leads to activation of the Hh-Gli pathway. Conversely, re-expression of SNF5 in MRT cells represses GLI1. Consistent with this, we show the presence of a Hh-Gli-activated gene expression profile in primary MRTs and show that GLI1 drives the growth of *SNF5*-deficient MRT cells *in vitro* and *in vivo*. Therefore, our studies reveal that SNF5 is a key mediator of Hh signaling and that aberrant activation of GLI1 is a previously undescribed targetable mechanism contributing to the growth of MRT cells.

© 2010 Nature America, Inc. All rights reserved.

Correspondence should be addressed to M.D. (marion.dorsch@sanofi-aventis.com) or C.W.M.R. (charles\_roberts@dfci.harvard.edu).

<sup>8</sup>These authors contributed equally to this work.

<sup>7</sup>Present address: Sanofi-Aventis, Cambridge, Massachusetts, USA.

#### AUTHOR CONTRIBUTIONS

Z.J. initiated the studies, conducted most of the experiments, analyzed data and wrote the manuscript. E.L.M.-B. conducted the *Gli1 in situ* experiments. C.G.S. generated Snf5-inactivated MEFs. E.S.M. contributed to Snf5 re-expression studies. B.W. assisted with ChIP studies. D.C. and J.M. conducted *in vivo* experiments. J.K. performed statistical analysis from interaction screen. P.T., Y.-J.C., J.P.M. and S.L.P. contributed to the gene expression analysis. M.T. and P.J.P. performed nucleosome repositioning assays. H.R., T.B., S.J.L. and J.F.K. contributed to the TAP-protein interaction screen. P.T.L.N. contributed to GLI1 shRNA studies. K.H. generated vectors for GLI1 deletions. S.B. contributed to the writing of the manuscript. M.W., W.R.S., C.W.M.R. and M.D. supervised the studies, assisted in data analysis and contributed to the writing of the manuscript.

Note: Supplementary information is available on the Nature Medicine website.

#### COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details accompany the full-text HTML version of the paper at <http://www.nature.com/naturemedicine/>.

The Hh pathway has critical functions in tissue patterning and differentiation during development<sup>1</sup>. Aberrant activation of the pathway resulting from mutations in the *PTCH1* gene (encoding Patched-1 receptor) and *SMO* gene (encoding the Smoothed homolog signal transducer) contribute to medulloblastoma and basal cell carcinomas<sup>3,4</sup>. In addition, amplifications in the *GLI1* transcription factor occur in gliomas and medulloblastomas<sup>5,6</sup>, and the oncogenic potential of *GLI1* has been validated in transgenic mouse models<sup>2</sup>. However, understanding of the precise mechanisms by which *GLI* transcription factors are regulated is limited. We thus sought to investigate the mechanism by which *GLI1* controls pathway activation.

We performed affinity purification–mass spectrometry (AP-MS) to identify proteins that interact with *GLI1*. We used tandem affinity purification (TAP) to isolate *GLI1* from mouse TM3 cells (Supplementary Fig. 1a,b), a Hh-responsive testicular epithelial cell line, and identified interacting proteins (Fig. 1a). The top-scoring interactor was *Sufu*, a *bona fide* *GLI1*-interacting protein that negatively regulates its activity<sup>7</sup>. Notably, the chromatin remodeling protein *Snf5* ( $E = 0.0022$ , false discovery rate  $P$  value = 0.0022) and several other SWI/SNF complex subunits, *Smarcc2* ( $E = 0.0186$ ,  $P = 0.0093$ ) and *Smarc1* ( $E = 0.0005$ ,  $P = 0.0005$ ), were among the top interactors of *GLI1* (Fig. 1a). AP-MS experiments with TAP-tagged *GLI2*, however, did not yield *Snf5* or its associated complex members (data not shown), thereby showing specificity in the interaction of *Snf5* with *GLI1*. To confirm the interaction, we performed immunoprecipitation of endogenous *Snf5* in TM3 cells transiently expressing *GLI1* and found that *GLI1* immunoprecipitated with *Snf5* (Fig. 1b). As a control, we repeated this with *SNF5*-deficient G401 human MRT cells. We did not detect *GLI1* in this case (Supplementary Fig. 1c), confirming that *GLI1* is only immunoprecipitated in the presence of *Snf5*. In TM3 cells transiently expressing various *GLI1* deletion mutants, we localized the interaction domain to the C terminus of *GLI1* outside of the activation domain (Supplementary Fig. 2a–c); this is a region less conserved among the three *GLI* proteins, supporting a specific interaction between *Snf5* and *GLI1*.

*Snf5* is a core member of the ATP-dependent SWI-SNF chromatin remodeling complex, which contributes to regulation of gene expression via modulation of chromatin structure<sup>8–10</sup>. Because *Ptch1* is a target of *GLI1*, as is *Gli1* itself<sup>11,12</sup>, we determined if *Snf5* associates with *Gli1*-regulated promoters by chromatin immunoprecipitation (ChIP), (Fig. 1c). Both *Snf5* and *GLI1* were enriched at regions upstream of the transcriptional start sites of both promoters (Fig. 1d,e).

We next tested the effect of shRNA-mediated knockdown of *Snf5* upon the expression of the *Gli1* target genes *Gli1* and *Ptch1*<sup>11,12</sup> (Fig. 2a) and found both to be upregulated (Fig. 2b). This is unlikely to be influenced by changes in expression of other Hh pathway components, as the expression of *Smo* and *Gli2* remained unaffected (Fig. 2b) and Hh ligands remained undetectable (data not shown). We further investigated this regulation in *Snf5* conditional knockout primary mouse embryonic fibroblasts (MEFs)<sup>13</sup>. Inactivation of *Snf5* (Fig. 2c) resulted in an eight- to tenfold increase in *Gli1* expression (Fig. 2d) and an approximately twofold increase in *Ptch1* expression (Supplementary Fig. 3a). As the SWI-SNF complex regulates nucleosome mobilization, we evaluated the effects of *Snf5* inactivation on nucleosome distribution at *Gli1*-target promoters and found that it led to a significant ( $P < 0.05$  for *Gli1* gene and  $P < 0.001$  for *Ptch1*, Fisher's exact test) decrease in the density of nucleosomes at the *Gli1* and *Ptch1* promoters (Supplementary Fig. 4a,b).

We evaluated whether *Snf5* controls *Gli1* expression during normal development *in vivo*. As the Hh pathway serves a key role in limb patterning, we used the Paired related homeobox (*Prx1*)-Cre transgenic mouse line<sup>14,15</sup> to inactivate *Snf5* in the early limb bud mesenchyme. We then examined the consequences of *Snf5* inactivation during early limb development.

*Gli1* transcripts are normally restricted to the posterior half of the developing limb (Fig. 2e) (reviewed in ref. 16). Inactivation of *Snf5* led to markedly increased levels of *Gli1* as well as ectopic expression throughout both anterior and posterior fields (Fig. 2e). Therefore, in all three experimental contexts, loss of *Snf5* leads to the upregulation of *Gli1*, demonstrating that *Snf5* normally has a role in restraining Hh-Gli signaling.

*Snf5* and *Brg1* are similar in that they are both *bona fide* tumor suppressors and core subunits of the SWI-SNF complex. However, the relationship between the two is complex, as residual activity of *Brg1* is essential for lymphoma formation driven by *Snf5* inactivation<sup>17</sup>. We therefore investigated their relationship in the regulation of *Gli1* activity. Inactivation of *Brg1* also resulted in a substantial increase in *Gli1* expression (Supplementary Fig. 5a,b), as did concurrent inactivation of *Snf5* and *Brg1* (Supplementary Fig. 5b). This suggests that *Gli1* is a common target of the SWI-SNF complex and may be central to the tumor suppressor activity of both *Snf5* and *Brg1*.

Biallelic inactivation of *SNF5* occurs in a majority of MRTs, which are poorly differentiated cancers arising in the kidney, brain (atypical teratoid rhabdoid tumors), liver and soft tissues<sup>18-20</sup>. Notably, *SNF5*-deficient tumor cells are diploid and genomically stable, suggesting that the major driver of malignancy upon *SNF5* loss consists of changes in epigenetically driven transcriptional control of gene expression<sup>21,22</sup>. We hypothesized that the Hh-Gli pathway is aberrantly activated in *SNF5*-deficient MRT cells. *GLI1* mRNA expression was indeed higher in MRT cell lines than in cancer cell lines of various origins (Fig. 3a). Re-expression of *SNF5* in two independent *SNF5*-deficient MRT cell lines (Fig. 3b and Supplementary Fig. 6a) led to a marked suppression of *GLI1* mRNA (Fig. 3c and Supplementary Fig. 6b). Therefore, *SNF5*-induced repression of *GLI1* in MRT cells is consistent with our findings that *Snf5* deficiency results in hyperactivation of the Hh-Gli pathway. Taken together, these findings suggest that *Snf5* normally is involved in limiting *Gli1* expression.

To investigate whether transcriptional upregulation of *GLI1* and its downstream targets occurs in primary human rhabdoid tumors, we analyzed microarray data from eight primary brain rhabdoid tumors, three MRT cell lines, 11 normal cerebellum samples and 25 primary medulloblastomas<sup>13,23</sup>. A subset of these medulloblastomas have genetic mutations in *PTCH1* and show an activated Hh pathway gene expression profile, thus serving as positive controls in our analyses<sup>23</sup>. Primary *SNF5*-deficient tumors indeed showed enrichment of gene expression associated with both Hh pathway activation ( $P = 2.72 \times 10^{-6}$ ), and *GLI1* overexpression signatures ( $P = 0.0063$ ) (Fig. 3d), similar to Hh-activated medulloblastomas ( $P = 0.00207$  for the Hh pathway and  $P = 0.00298$  for the *GLI1* overexpression gene sets) and to basal cell carcinomas ( $P = 1.19 \times 10^{-7}$ ), which often possess activating mutations in the Hh pathway (Fig. 3d). A *Snf5*-null gene expression signature<sup>13</sup> and *CYCLIN-D1* overexpression signature were used as controls<sup>24</sup>, showing expected trends in the primary rhabdoid tumors (Supplementary Fig. 7a).

We next evaluated whether upregulation of *GLI1* is required for the proliferation of *SNF5*-deficient cells. Doxycycline-inducible, shRNA-mediated knockdown of *GLI1* in three MRT cell lines (Fig. 4a and Supplementary Fig. 8a) resulted in impaired proliferation (Fig. 4b-d and Supplementary Fig. 8c,d) as well as in the inhibition of colony formation (Fig. 4e). Proliferation was rescued by overexpression of a doxycycline-inducible *GLI1* construct not containing the shRNA recognition sequence (Fig. 4c). To determine whether *GLI1* is necessary for the growth of rhabdoid tumors *in vivo*, we established subcutaneous xenografts of G401 cells in severe combined immunodeficient (SCID) mice, which lack T and B cells, using the doxycycline-inducible cells. In contrast to vehicle treatments, treatment of mice with doxycycline depleted *GLI1* protein (Supplementary Fig. 8b) and markedly inhibited

tumor growth (Fig. 4f). Treatment of MRT cells with a small-molecule inhibitor of GLI, Hedgehog pathway inhibitor-1 (HPI-1)<sup>25</sup>, similarly led to dose-dependent decreases in *GLI1* transcripts and inhibition of cell proliferation (Supplementary Fig. 9a–d). In contrast, treatment with a highly specific SMO antagonist, NVP-LDE225 (ref. 26) had no effect on GLI1 expression or proliferation of *SNF5*-deficient MRT cells (Supplementary Figs. 10a–d), as would be expected if Hh activation occurs downstream of SMO through activation of GLI1. Collectively, these results show an essential role for GLI1 in the proliferation of *SNF5*-deficient cancer cells. Finally, our preliminary findings indicate that Snf5 interacts with GLI1 even upon stimulation of the pathway with an agonist (Supplementary Fig. 11a,b). This suggests that Snf5 could functionally prevent hyperactivation of the pathway, although the precise mechanisms will need to be addressed.

Transcriptional activity is regulated by nucleosome position and density, with more open chromatin structure and decreased nucleosomal density occurring at the promoters of highly transcribed genes. Our findings suggest a model whereby the SWI-SNF complex physically interacts with GLI1 to directly regulate activity of the Hh pathway via control of chromatin structure at GLI1 target promoters. Although we have demonstrated that the tumor-suppressor effects of SNF5 require interaction with GLI1, SNF5 has other interactions of potential cancer relevance, such as with the oncoprotein c-Myc and the tumor suppressor p53 (refs. 27–30). We thus suggest a mechanistic model whereby loss of SNF5 drives cancer formation through simultaneous epigenetic perturbation of GLI1 and other key cancer-promoting pathways, several of which may thus constitute viable therapeutic targets.

In evaluating the relevance of SNF5 regulation of GLI1, we show that *SNF5*-deficient MRT cells have hyperactivated GLI signaling, which has a role in their growth. Our studies reveal a previously undiscovered mechanism controlling the Hh pathway that has potential therapeutic implications for an aggressive cancer for which no targeted therapy currently exists. For cancers with proximal activation of the Hh pathway, treatment with SMO inhibitors has shown clinical efficacy and little toxicity<sup>31</sup>. However, as Hh pathway activation can occur downstream of SMO, as we demonstrate in *SNF5*-deficient MRT cells, our studies provide further understanding and a rationale for the inhibition of GLI1 in targeted cancer treatment.

## ONLINE METHODS

### Tandem affinity purification-tagged–proteins and mass spectrometry

Human GLI1 was tagged at the C terminus with the TAP tag and stably expressed in TM3 cells (American Type Culture Collection) by retrovirus-mediated gene transfer<sup>32</sup>. Mouse TM3 cells are commonly used in studies pertaining to Hh signal transduction because they show an increase in *Gli1* and *Ptch1* transcripts in response to stimulation with a Smo agonist<sup>33</sup>. GLI1 transduction was verified by immunoblotting, and GLI1-TAP-containing protein complexes were subsequently purified from nuclear extracts and subjected to one-dimensional SDS-PAGE. Gel lanes were cut into slices across the full separation range and subjected to in-gel tryptic digestion. Peptide mass and fragmentation data obtained by liquid chromatography–tandem mass spectrometry were used to query a version (curated in house) of the International Protein Index database using Mascot (Matrix Science)<sup>32</sup>. Statistical analysis of candidate GLI1 protein interactors was performed using the binomial test (described in the Supplementary Methods).

### Chromatin immunoprecipitation assay

TM3 cells were grown to subconfluence, and cross-linking was performed with disuccinimidyl glutarate (2 mM; Pierce Biotech) followed by formaldehyde (1%). Cells

were lysed in 0.5% SDS lysis buffer followed by sonication with a Misonix 3000 sonicator for a total of 4 min (30-s pulses with 30-s rests, power 3.5). Lysates were processed using standard ChIP procedures<sup>34</sup> using a control rabbit IgG, V5-specific antibody (ChIP grade; Abcam, cat. no. 9116) or a Snf5 antibody (Bethyl Laboratories, cat. no. A301-087A). Quantitative PCR was performed with the SYBR Green master mix (Applied Biosystems), and enrichment was calculated using the percentage-of-input method (see ChIP analysis online guide; <http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/RNAi-Epigenetics-and-Gene-Regulation/Chromatin-Remodeling/Chromatin-Immunoprecipitation-ChIP/chip-analysis.html>). Primers were designed to amplify the promoter regions of the mouse *Ptch1* and *Gli1* genes (see Supplementary Methods), some in proximity to sequences resembling consensus Gli1 binding sites.

### Generation of Snf5-deficient primary mouse embryonic fibroblasts

Primary MEFs were collected from embryos at day 13.5 and maintained in DMEM (10% FCS, 2mM L-glutamine, nonessential amino acids, and 100 U penicillin-streptomycin per ml (Gibco)). Inactivation of Snf5, Brg1, or Snf5 and Brg1 was achieved with retroviral infection with pBabe-puro<sup>R</sup>-Cre (vector backbone from AddGene, plasmid 1764). Cells were selected in medium containing puromycin (2.5 µg ml<sup>-1</sup>) (Clontech) 48 h after infection.

### Mouse strains

Conditional *Snf5* loss-of-function mutant mice (*Snf5*<sup>fl/fl</sup>; *Prx1*-Cre) were generated by intercrossing *Prx1*-Cre transgenic mice<sup>14</sup> with mice carrying the floxed *Snf5* allele<sup>35</sup>.

### In situ hybridizations

Whole-mount *in situ* hybridizations were performed essentially as described in ref. 36 using nonradioactive digoxigenin (DIG)-labeled probes generated according to the manufacturer's instructions (Roche). The *Gli1* probe was generously provided by C. Tabin.

### Microarray analysis and signature projection methodology

Snap-frozen tumor ATRT and medulloblastoma samples were obtained from brain tumor resections performed at Children's Hospital Boston under approval from its Institutional Review Board. Informed consent was obtained in all cases. Total RNA was isolated using Trizol reagent (Invitrogen) per the manufacturer's protocol. RNA was applied to Affymetrix U133A2 arrays, and CEL files (CEL files are Affymetrix files with intensity calculations on the pixel values of the Affymetrix DAT files; for more details see <http://www.affymetrix.com/estore/support/developer/powertools/changelog/gcos-agcc/cel.html.affx>) were preprocessed using robust multiarray averaging<sup>37</sup>. Arrays were visualized using GenePattern software (<http://www.broadinstitute.org/cancer/software/genepattern/>). For each gene set of interest (for example, Snf5-null) we defined a numerical score to represent the single-sample absolute enrichment in each of the samples following a previously described procedure<sup>38</sup>. Briefly, we preprocessed the gene-expression data set by mapping Affymetrix gene probes to gene symbols using the gene set enrichment analysis desktop application (GSEA)<sup>39</sup>. The mapping of gene probes to gene symbols is done by selecting 'collapse' in the tools menu and then choosing the 'by-max' parameter. Genes were ranked by absolute expression for each sample. The enrichment score was produced by evaluating a weighted integral (sum) of the difference between the empirical cumulative distribution functions (ECDF) of the genes in the gene set versus the genes not in the set, rather than by using the maximum (Kolmogorov-Smirnov) as used in GSEA. For gene sets with upregulated and downregulated versions, a combined score was produced by subtracting the downregulated from the upregulated scores). To quantify the degree of matching between phenotypes and pathway profiles, we used the area under the receiver



operating characteristic (ROC) curve ranging from 0.5 (random match) to 1.0 (perfect match). Statistical significance was computed with a binomial test. Both computations use the R ‘verification’ package (<http://cran.r-project.org/web/packages/verification/index.html>).

### ***In vivo* efficacy study of doxycycline-inducible GLI1 shRNA**

SCID/beige mice (Charles River Laboratories) were allowed to acclimate in the Novartis Institutes for BioMedical Research animal facility with *ad libitum* access to food and water for at least 3 d before manipulation. Mice were handled in accordance with Novartis Animal Care and Use Committee protocols and regulations. Stably infected G401 cells were free of mycoplasma and viral contamination (Infectious Microbe PCR Amplification Test, Research Animal Diagnostic Laboratory, University of Missouri). Mice (8 weeks old) were inoculated subcutaneously with  $5 \times 10^6$  cells in 50% Matrigel (BD Biosciences) in the right dorsal axillary region. Tumor dimensions were obtained with calipers, and tumor volume was calculated as  $(l \times w^2) / 2$ , where  $l$  represents length and  $w$  represents width. Nine days after implantation, mice were randomized and sorted into treatment groups ( $n = 8$  per group) on the basis of tumor volume (mean, 184–211 mm<sup>3</sup>). Mice received vehicle (5% sucrose) or doxycycline (Sigma-Aldrich) (1mg ml<sup>-1</sup> in 5% sucrose) via oral gavage for the duration of the study.

### **Statistical analyses**

The binomial statistical method was used to calculate significance of candidate interactors in the protein-protein interaction screen and is further described in Supplementary Methods. Statistical significance for the gene signature projection was calculated using the binomial test and that of nucleosome density was computed using Fisher’s exact test. In all cases,  $p < 0.05$  was considered to indicate statistical significance.

### **Additional methods**

Detailed methodology is described in the Supplementary Methods.

### **Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

### **Acknowledgments**

We thank X. Wang, A. Bouret, J. DaSilva and A. Carlson for their assistance and S. S. Kadam for critical advice. The *Gli1* probe was generously provided by C. Tabin (Harvard University Medical School).


### **References**

1. Jiang J, Hui CC. Hedgehog signaling in development and cancer. *Dev Cell*. 2008; 15:801–812. [PubMed: 19081070]
2. Ruiz i Altaba A, Mas C, Stecca B. The Gli code: an information nexus regulating cell fate, stemness and cancer. *Trends Cell Biol*. 2007; 17:438–447. [PubMed: 17845852]
3. Gailani MR, et al. The role of the human homologue of *Drosophila* patched in sporadic basal cell carcinomas. *Nat Genet*. 1996; 14:78–81. [PubMed: 8782823]
4. Raffel C, et al. Sporadic medulloblastomas contain PTCH mutations. *Cancer Res*. 1997; 57:842–845. [PubMed: 9041183]
5. Kinzler KW, et al. Identification of an amplified, highly expressed gene in a human glioma. *Science*. 1987; 236:70–73. [PubMed: 3563490]
6. Northcott PA, et al. Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. *Nat Genet*. 2009; 41:465–472. [PubMed: 19270706]

7. Kogerman P, et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. *Nat Cell Biol.* 1999; 1:312–319. [PubMed: 10559945]
8. Roberts CW, Orkin SH. The SWI/SNF complex—chromatin and cancer. *Nat Rev Cancer.* 2004; 4:133–142. [PubMed: 14964309]
9. Weissman B, Knudsen KE. Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. *Cancer Res.* 2009; 69:8223–8230. [PubMed: 19843852]
10. Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. *Cell.* 2009; 136:200–206. [PubMed: 19167321]
11. Goodrich LV, Johnson RL, Milenkovic L, McMahon JA, Scott MP. Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. *Genes Dev.* 1996; 10:301–312. [PubMed: 8595881]
12. Lee J, Platt KA, Censullo P, Ruiz i Altaba A. Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. *Development.* 1997; 124:2537–2552. [PubMed: 9216996]
13. Isakoff MS, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. *Proc Natl Acad Sci USA.* 2005; 102:17745–17750. [PubMed: 16301525]
14. Logan M, et al. Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. *Genesis.* 2002; 33:77–80. [PubMed: 12112875]
15. Martin JF, Olson EN. Identification of a prxl limb enhancer. *Genesis.* 2000; 26:225–229. [PubMed: 10748458]
16. Theil T, Kaesler S, Grotewold L, Bose J, Ruther U. Gli genes and limb development. *Cell Tissue Res.* 1999; 296:75–83. [PubMed: 10199967]
17. Wang X, et al. Oncogenesis caused by loss of the SNF5 tumor suppressor is dependent on activity of BRG1, the ATPase of the SWI/SNF chromatin remodeling complex. *Cancer Res.* 2009; 69:8094–8101. [PubMed: 19789351]
18. Biegel JA, et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. *Cancer Res.* 1999; 59:74–79. [PubMed: 9892189]
19. Sévenet N, et al. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. *Am J Hum Genet.* 1999; 65:1342–1348. [PubMed: 10521299]
20. Versteeg I, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. *Nature.* 1998; 394:203–206. [PubMed: 9671307]
21. McKenna ES, et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. *Mol Cell Biol.* 2008; 28:6223–6233. [PubMed: 18710953]
22. McKenna ES, Roberts CW. Epigenetics and cancer without genomic instability. *Cell Cycle.* 2009; 8:23–26. [PubMed: 19098432]
23. Pomeroy SL, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature.* 2002; 415:436–442. [PubMed: 11807556]
24. Wisniewski D, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. *Cancer Res.* 2002; 62:4244–4255. [PubMed: 12154026]
25. Hyman JM, et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. *Proc Natl Acad Sci USA.* 2009; 106:14132–14137. [PubMed: 19666565]
26. Pan S, et al. Discovery of NVP-LDE225, a potent and selective smoothed antagonist. *ACS Med Chem Lett.* 2010; 1:130–134.
27. Chai J, Charboneau AL, Betz BL, Weissman BE. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. *Cancer Res.* 2005; 65:10192–10198. [PubMed: 16288006]
28. Lee D, et al. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. *J Biol Chem.* 2002; 277:22330–22337. [PubMed: 11950834]
29. Nagl NG Jr, Zweitzig DR, Thimmapaya B, Beck GR Jr, Moran E. The c-myc gene is a direct target of mammalian SWI/SNF-related complexes during differentiation-associated cell cycle arrest. *Cancer Res.* 2006; 66:1289–1293. [PubMed: 16452181]


30. Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV. Genetic ablation of cyclin D1 abrogates genesis of rhabdoid tumors resulting from *Ini1* loss. *Proc Natl Acad Sci USA*. 2005; 102:12129–12134. [PubMed: 16099835]
31. Rudin CM, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. *N Engl J Med*. 2009; 361:1173–1178. [PubMed: 19726761]
32. Bouwmeester T, et al. A physical and functional map of the human TNF- $\alpha$ /NF- $\kappa$ B signal transduction pathway. *Nat Cell Biol*. 2004; 6:97–105. [PubMed: 14743216]
33. Frank-Kamenetsky M, et al. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothed agonists and antagonists. *J Biol*. 2002; 1:10. [PubMed: 12437772]
34. Turner FB, Cheung WL, Cheung P. Chromatin immunoprecipitation assay for mammalian tissues. *Methods Mol Biol*. 2006; 325:261–272. [PubMed: 16761732]
35. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene *Snf5*. *Cancer Cell*. 2002; 2:415–425. [PubMed: 12450796]
36. Riddle RD, Johnson RL, Laufer E, Tabin C. Sonic hedgehog mediates the polarizing activity of the ZPA. *Cell*. 1993; 75:1401–1416. [PubMed: 8269518]
37. Irizarry RA, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. *Biostatistics*. 2003; 4:249–264. [PubMed: 12925520]
38. Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature*. 2009; 462:108–112. [PubMed: 19847166]
39. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005; 102:15545–15550. [PubMed: 16199517]






**Figure 1.**

Snf5 interacts with GLI1 and localizes to Gli1 regulated promoters. **(a)** All proteins precipitated by TAP-GLI1 and detected by mass spectrometry are indicated by a single data point. The y axis shows the  $\log_{10}$  fold ratios comparing the frequency with which each mouse protein was detected in the TAP-GLI1 protein purifications relative to the 26 TAP-protein purifications in our entire mouse database. The x axis shows the associated expected (E) values calculated using binomial statistics corrected for multiple hypotheses (false discovery rate-corrected *P* values not shown). **(b)** Immunoblot of GLI1 in whole-cell lysates from TM3 cells transfected with a vector control (pcdna) or GLI1-V5-tagged vector (shown in the first two lanes), and from GLI1-V5 expressing lysates subjected to immunoprecipitation (IP) of endogenous Snf5 with a Snf5-specific antibody or a control IgG (as indicated in lanes three through six). **(c)** Schematic of the mouse *Gli1* and *Ptch1* promoters showing locations of primers relative to the ATG translation initiation site. The arrow shows the location of the transcriptional start site (TSS) and the asterisk (\*) denotes proximity of the primer set to sequences resembling the Gli1 recognition sequence. **(d,e)** Quantitative PCR (qPCR) with primers binding the locations depicted in **c**, showing percentage input recoveries of Snf5 and GLI1 at the *Gli1* **(d)** and *Ptch1* **(e)** promoters in ChIP performed with TM3 GLI1-V5 cells with a Snf5-specific antibody, a V5-specific antibody or a rabbit IgG. qPCR was performed in triplicate and input recovery (%) is shown as mean  $\pm$  s.d. Ctl, control.


**Figure 2.**

Loss of Snf5 leads to activation of the Hh-Gli pathway *in vitro* and *in vivo*. **(a)** Immunoblot showing reduction of Snf5 protein in TM3 cells expressing Snf5-targeting shRNA but not TM3 cells expressing nontargeting control (Ctl) shRNA. Gapdh, glyceraldehyde 3-phosphate dehydrogenase. **(b)** Quantitative RT-PCR showing expression of *Snf5*, *Gli1*, *Gli2*, *Ptch1* and *Smo* mRNA in TM3 cells expressing shRNA targeting Snf5. Values are shown as mean  $\pm$  s.d. **(c)** Immunoblot showing loss of Snf5 protein in Cre recombinase-treated *Snf5*<sup>fl/fl</sup> (fl1 and fl2 are duplicate samples) primary MEFs;  $\beta$ -actin is shown as a loading control. **(d)** Quantitative RT-PCR showing expression of *Gli1* mRNA in the above (same as in **c**) Cre-treated *Snf5*<sup>fl/fl</sup> MEFs (labeled as *Snf5*<sup>fl/fl</sup>-1, *Snf5*<sup>fl/fl</sup>-2). The experiment was performed in duplicate, and expression is shown as mean  $\pm$  s.d. **(e)** *In situ* hybridization showing the expression of *Gli1* in the limb buds of littermate control (*Snf5*<sup>fl/fl</sup>; *Prx1*-Cre) and Snf5-deficient (*Snf5*<sup>fl/fl</sup>; *Prx1*-Cre) embryos at day 11.5. Boxed regions are enlarged beneath their respective images. WT, wild type.



**Figure 3.**

The Hh-Gli pathway is activated in MRT cell lines and primary tumors. **(a)** Quantitative RT-PCR of expression of *GLI1* relative to  $\beta$ -actin in MRT cells (A204, G401, BT12 and BT16) and in glioblastoma (U87MG and LN229), medulloblastoma (DAOY), melanoma (A2058 and A375), multiple myeloma (LP1 and RPMI-8226), breast (MDA-MB231 and MCF7) and pancreas (MiaPaca, PANC1) cancer cell lines. **(b)** Immunoblot of SNF5 expression in G401 cells after 5 d of selection following retroviral infection with a SNF5-expressing vector or a control vector (Ctl);  $\beta$ -actin is shown as a loading control. **(c)** Quantitative RT-PCR showing *GLI1* expression in Ctl vector-transduced and SNF5-expressing G401 cells. The experiment shown is representative of three independent experiments, and values represent mean  $\pm$  s.d. of triplicate samples. **(d)** Heat map showing the single-sample signature profiles using the Hh signaling pathway, basal cell carcinoma (BCC) and GLI1-induced gene expression gene sets in a multi-tumor gene expression panel. ATRT, primary brain MRTs; MRT, three MRT cell lines; NC, normal cerebellum; MD, medulloblastoma; MD SHH, medulloblastoma with Hh pathway activation.

**Figure 4.**

Inhibition of GLI1 impairs proliferation of MRT cells. **(a)** Immunoblot showing reduction of GLI1 protein in G401 cells upon induction with doxycycline (dox) of GLI1 shRNAs or of a nontargeting control (Ctl) shRNA. GLI1 is overexpressed upon doxycycline treatment in cells carrying both the inducible GLI1 shRNA and inducible GLI1 vectors; Gapdh is included as a loading control. **(b)** BrdU assay showing cell proliferation over a time course of doxycycline induction of GLI1 shRNA-1 or Ctl shRNAs in G401 cells. **(c)** BrdU time-course assay in G401 cells showing cell proliferation following doxycycline-induced expression of a control (Ctl) shRNA, GLI1 shRNA-2 or GLI1shRNA-2 accompanied by expression of a doxycycline-inducible GLI1 construct not containing the shRNA recognition sequence. **(d)** BrdU assay in A204 cells showing cell proliferation following doxycycline induction of Ctl, GLI1 shRNA-1 and GLI1shRNA-2. All assays were performed in triplicate, and BrdU incorporation in doxycycline-treated cells is represented as percentage of BrdU label compared to uninduced cells. Values are shown as mean  $\pm$  s.d. **(e)** Colony formation in A204 cells in the absence and presence of doxycycline induction of Ctl shRNA, GLI1 shRNA-1 and GLI1 shRNA-2. A representative experiment of at least three independent experiments performed in triplicate is shown. **(f)** Tumor volumes over a time course of vehicle- and doxycycline-treated animals bearing G401 MRT cells containing inducible GLI1 shRNA-1. Tumor volume is reported as mean  $\pm$  s.e.m.;  $n = 8$  per treatment group.